BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36070463)

  • 21. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis.
    Wongjarupong N; Assavapongpaiboon B; Susantitaphong P; Cheungpasitporn W; Treeprasertsuk S; Rerknimitr R; Chaiteerakij R
    BMC Gastroenterol; 2017 Dec; 17(1):149. PubMed ID: 29216833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of Non-alcoholic Fatty Liver Disease in Iran: A Systematic Review and Meta-analysis.
    Tabaeian SP; Rezapour A; Azari S; Martini M; Saran M; Behzadifar M; Shahabi S; Sayyad A; Tahernejad A; Bragazzi NL; Ehsanzadeh SJ; Behzadifar M
    J Clin Exp Hepatol; 2024; 14(1):101209. PubMed ID: 38076354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.
    Cao L; An Y; Liu H; Jiang J; Liu W; Zhou Y; Shi M; Dai W; Lv Y; Zhao Y; Lu Y; Chen L; Xia Y
    BMC Med; 2024 Mar; 22(1):101. PubMed ID: 38448943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.
    Rich NE; Oji S; Mufti AR; Browning JD; Parikh ND; Odewole M; Mayo H; Singal AG
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):198-210.e2. PubMed ID: 28970148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.
    Younossi ZM; Golabi P; Paik JM; Henry A; Van Dongen C; Henry L
    Hepatology; 2023 Apr; 77(4):1335-1347. PubMed ID: 36626630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mortality and Liver-Related Events in Lean Versus Non-Lean Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
    Ha J; Yim SY; Karagozian R
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2496-2507.e5. PubMed ID: 36442727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
    Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB
    Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiplatelet therapy associated with lower prevalence of advanced liver fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Thongtan T; Deb A; Vutthikraivit W; Laoveeravat P; Mingbunjerdsuk T; Islam S; Islam E
    Indian J Gastroenterol; 2022 Apr; 41(2):119-126. PubMed ID: 35318571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.
    Musso G; Gambino R; Tabibian JH; Ekstedt M; Kechagias S; Hamaguchi M; Hultcrantz R; Hagström H; Yoon SK; Charatcharoenwitthaya P; George J; Barrera F; Hafliðadóttir S; Björnsson ES; Armstrong MJ; Hopkins LJ; Gao X; Francque S; Verrijken A; Yilmaz Y; Lindor KD; Charlton M; Haring R; Lerch MM; Rettig R; Völzke H; Ryu S; Li G; Wong LL; Machado M; Cortez-Pinto H; Yasui K; Cassader M
    PLoS Med; 2014 Jul; 11(7):e1001680. PubMed ID: 25050550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: a systematic review and meta-analysis.
    Shea S; Lionis C; Kite C; Lagojda L; Uthman OA; Dallaway A; Atkinson L; Chaggar SS; Randeva HS; Kyrou I
    Front Endocrinol (Lausanne); 2024; 15():1357664. PubMed ID: 38689730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
    Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
    J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease.
    Tovoli F; Ferri S; Piscaglia F
    Curr Pharm Des; 2020; 26(32):3909-3914. PubMed ID: 32348210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world.
    Henry L; Paik J; Younossi ZM
    Aliment Pharmacol Ther; 2022 Sep; 56(6):942-956. PubMed ID: 35880713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040.
    Ito T; Ishigami M; Zou B; Tanaka T; Takahashi H; Kurosaki M; Maeda M; Thin KN; Tanaka K; Takahashi Y; Itoh Y; Oniki K; Seko Y; Saruwatari J; Kawanaka M; Atsukawa M; Hyogo H; Ono M; Ogawa E; Barnett SD; Stave CD; Cheung RC; Fujishiro M; Eguchi Y; Toyoda H; Nguyen MH
    Hepatol Int; 2021 Apr; 15(2):366-379. PubMed ID: 33580453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Global Prevalence of Nonalcoholic Fatty Liver Disease and its Association With Cancers: Systematic Review and Meta-Analysis.
    Muhamad NA; Maamor NH; Leman FN; Mohamad ZA; Bakon SK; Abdul Mutalip MH; Rosli IA; Aris T; Lai NM; Abu Hassan MR
    Interact J Med Res; 2023 Jul; 12():e40653. PubMed ID: 37467012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modelling NAFLD disease burden in four Asian regions-2019-2030.
    Estes C; Chan HLY; Chien RN; Chuang WL; Fung J; Goh GB; Hu TH; Huang JF; Jang BK; Jun DW; Kao JH; Lee JW; Lin HC; Razavi-Shearer K; Seto WK; Wong GL; Wong VW; Razavi H
    Aliment Pharmacol Ther; 2020 Apr; 51(8):801-811. PubMed ID: 32133676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis.
    Houttu V; Bouts J; Vali Y; Daams J; Grefhorst A; Nieuwdorp M; Holleboom AG
    Front Endocrinol (Lausanne); 2022; 13():1032164. PubMed ID: 36407307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study.
    Swain MG; Ramji A; Patel K; Sebastiani G; Shaheen AA; Tam E; Marotta P; Elkhashab M; Bajaj HS; Estes C; Razavi H
    CMAJ Open; 2020; 8(2):E429-E436. PubMed ID: 32518095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.